Carnival Corp., the world's largest cruise company, gave no clarity about when it will cruise again in a company filing released to investors on Thursday. During the company's second quarter, which ended on May 31, it saw a net loss of $4.4 billion, or $6.07 earnings per share, preliminary results show. It is accelerating plans […]...
(Bloomberg Opinion) -- Less than a month ago, Wirecard AG told investors that it expected an “unqualified audit opinion” when its long-delayed annual results were finally published. The update that the German electronic-payments processor provided to the market on Wednesday was about as far from unqualified as it’s possible to imagine.Auditor Ernst & Young has been unable to obtain enough information to verify 1.9 billion euros ($2.1 billion) of the company’s cash balances, according to the Wirecard statement. Furthermore, there’s evidence that a third party tried to “deceive” the auditor. The annual report still hasn’t been published and, unless that’s quickly resolved, creditors might terminate 2 billion euros of loans to the company. The shares lost about two-thirds of their already beaten-down value. Since their peak in 2018, when Wirecard replaced Commerzbank AG in Germany’s blue-chip Dax index, about 20 billion euros of shareholder wealth has gone up in smoke. The market capitalization is...
All five patients in an early-stage trial given the one-time treatment, giroctocogene fitelparvovec, did not have spontaneous bleeding episodes or require infusions of the blood-clotting protein they otherwise lack, the companies said. Pfizer and Sangamo's therapy is one of several treatments being developed for hemophilia A, as an alternative to the current practice that requires regular infusions to replace the missing protein, factor VIII. On Wednesday, a rival gene therapy by BioMarin Pharmaceutical Inc was found to reduce bleeding episodes by over 90% in patients treated four years ago....
